Ann: Appendix 4C September Quarterly 2015, page-18

I find it funny that some posters here talk about sp dropping if POC1 wasnt involved

Honestly - What part of Anteo's current $75m mcap is attributed to them - Bugger All

If you think POC1 is the big opportunity you have totally missed what is going on here IMO

The good thing about Anteo is that risk is spread across multiple markets and customers etc etc

At current MCAP no one customer has any weighting on current sp IMO

Anteo now have their own products and are selling direct to customers through supply agreements

* Diasource Acquisition plus Sigma / Komo / Veritas distributors etc etc

* Batteries

* Cook

* New Appointment - Ex Diasorin President

* US Reference Lab - Named yet no one notices

* AMG products selling into POC LATERAL FLOW tests for Pregnancy - "$1.68 billion of pregnancy tests are sold globally each year."

"DIAsource has a significant library of monoclonal antibodies whose value can be enhanced through the use of Anteo products such as the AMG™ Coupling Kit, 200 nm Magnetic Particles for use in Point of Care applications."

Lets see where we are by AGM